Industry News
Pharmaceutical Industry News
The combination of Padcev and…
The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. Fosun Pharma is out-licensing its DPP1 inhibitor
Trump’s Tariffs Set to Hit Ireland, Where Drugmakers Play Tax Games
Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a world without President Trump’s tariffs.
While Sanofi originally had its…
While Sanofi originally had its eye on tolebrutinib when it purchased its partner Principia Biopharma for $3.7 billion, another of the biotech’s BTK inhibitors has made it across the FDA finish line first.
Eli Lilly said it has “intensified…
Eli Lilly said it has "intensified efforts to align prices across developed countries" in recent months. Besides a new U.K. price hike, Lilly said it may make other "necessary pricing adjustments" by Sept. 1.
An analysis of how cancer…
An analysis of how cancer drugmakers interact with oncologists found, perhaps unsurprisingly, that those interactions are dominated by therapies boasting a broad reach and targeting the most common cancers.
Despite a threat from President…
Despite a threat from President Donald Trump early last week that the administration's policy on pharmaceutical tariffs would come “within the next week or so,” his much-anticipated announcement is still “weeks away,” Reuters reports.
Chinese authorities did not renew…
Chinese authorities did not renew a conditional approval of Green Valley Pharmaceuticals’ controversial Alzheimer’s disease drug sodium oligomannate, also known as GV-971, according to online records.
President Donald Trump has inked a…
President Donald Trump has inked a new executive order calling on the HHS’ Administration for Strategic Preparedness and Response to identify and stockpile active pharmaceutical ingredients for roughly 26 medicines the agency deems essential.
Sana Biotechnology will turn to…
Sana Biotechnology will turn to CDMOs for manufacturing and pause its plant build-out in Bothell, Washington. The company opened the facility a year ago.
As it continues development of its…
As it continues development of its rademikibart for asthma and other inflammatory diseases, Connect Biopharma is teaming up with former pro football player Elbert “Ickey” Woods to drive asthma awareness across the U.S.
Generic versions of CSL’s iron…
Generic versions of CSL’s iron replacement therapy Venofer have arrived in the U.S. after Viatris had initially touted a potential launch in 2022.
The National Advertising Division…
The National Advertising Division has sided with Genomic Health in a challenge the Exact Sciences subsidiary brought against fellow cancer diagnostics maker Agendia.
As parent company Maravai rolls…
As parent company Maravai rolls out a $50 million cost-savings drive, 90 staffers from its CDMO subsidiary TriLink are also set to lose their jobs, according to a recent layoff notice filed with the state
Discover how Fedegari’s FOB5 is…
Discover how Fedegari’s FOB5 is redefining sterilization with compact design, GMP compliance & high-containment capabilities.
Vor Bio’s big bet on RemeGen’s…
Vor Bio’s big bet on RemeGen’s autoimmune asset telitacicept appears well placed after the drug—already approved across three conditions overseas—delivered a late-stage win in a Sjögren's syndrome trial in China.
Merck has begun the 8% reduction…
Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of 58 employees at its headquarters in Rahway, New Jersey.
VML Health has stepped up its work…
VML Health has stepped up its work on advanced technology, data and AI-enabled strategies by naming Jason Reese global chief transformation officer.
Texas Attorney General Ken Paxton…
Texas Attorney General Ken Paxton and Health Choice Alliance are accusing Eli Lilly of “incentivizing” providers in the state to prescribe its drugs, including the popular diabetes and obesity medications Mounjaro and Zepbound.
As pharmas play up their U.S….
As pharmas play up their U.S. investment plans during the second Trump administration, the particulars of one project at AbbVie are coming into focus.
Robin Marcus shares how Marken is…
Robin Marcus shares how Marken is expanding patient access, supporting trial sites and driving breakthroughs in decentralized research.